Mexico's Genomma in market-maker program

Mexico-based drugmaker Genomma Lab Internacional says it has signed an agreement with IXE Casa de Bolsa to act as the market-maker for the  company's outstanding shares, thus becoming another participant in the  program. The contract will become valid upon approval of the Mexican  Stock Exchange (Bolsa Mexicana de Valores) and will be in effect for a  minimum period of 12 months from the date of the agreement.

Less than six months since becoming a public company, Genomma Lab is  seeking to leverage the benefits of the modernizing Mexican markets via  the market-maker program. The company expects that its incorporation  into this program will allow for increased share liquidity.